Lord, Abbett & Co’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Lord, Abbett & Co’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-178,608	Closed	-$23.5M	–	720
2020 Q4	$23.5M	Buy	178,608 +40,708	+30%	+$3.6M	0.06%	385
2020 Q3	$6.97M	Sell	137,900 -14,664	-10%	-$659K	0.02%	526
2020 Q2	$7.27M	Sell	152,564 -134,862	-47%	-$6.27M	0.03%	520
2020 Q1	$14.1M	Sell	287,426 -71,185	-20%	-$3.63M	0.06%	375
2019 Q4	$20.6M	Sell	358,611 -164,404	-31%	-$8.14M	0.07%	382
2019 Q3	$18.8M	Sell	523,015 -51,451	-9%	-$2.01M	0.06%	417
2019 Q2	$17.9M	Buy	574,466 +286,244	+99%	+$7.76M	0.06%	444
2019 Q1	$6.76M	Buy	+288,222	New	+$4.62M	0.02%	621

Lord, Abbett & Co's EIDX Position: Q1 2021 in Review

Lord, Abbett & Co sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 178,608 shares — an estimated $23.5M sold.

Lord, Abbett & Co first reported a position in EIDX in Q1 2019 and held it in 8 quarters. The position peaked at $23.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Lord, Abbett & Co reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Lord, Abbett & Co sold 178,608 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $23.5M.
Lord, Abbett & Co first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
Lord, Abbett & Co's Eidos Therapeutics, Inc. Common Stock position peaked at $23.5M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.